Table 1.
Studies included in meta-analysis
| Study | Year | Country | Stage | No. of Patients | Inclusion Period | AB | Dilution | Site | Age (year) | Follow-Up | Outcome | Cytoplasm Nuclear | Preserved SMAD4 (%) | Adjusted Therapy |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Alazzouzi [15] | 2005 | Finland | III | 86 | 1993-1997 | Santa Cruz Biotechnology Inc | 1:1000 | Colon/rectum | Mean, 70.1 | At least 6 years | DFS and OS | NA | 26 | No |
| Alhopuro [5] | 2005 | Finland | III | 75 | 1994-1998 | Santa Cruz Biotechnology Inc | 1:1000 | Colon/rectum | Mean, 59 | Mean, 8.7 years | DFS and OS | NA | 86.7 | Yes |
| Isaksson-Mettävainio [18] | 2006 | Sweden | I-III | 86 | 1987-1994 | Santa Cruz Biotechnology Inc | 1:50 | Colon/rectum | NA | NA | CSS | Nuclear | 90.7 | No |
| Bacman [17] | 2007 | Germany | II-III | 305 | 1991-2001 | Santa Cruz Biotechnology Inc | 1:50 | Colon | Median, 64 | Median, 91 months | CSS | Nuclear | 85.6 | Yes |
| Mesker [19] | 2009 | Netherlands | I-II | 118 | 1980-2001 | Santa Cruz Biotechnology Inc | 1:400 | Colon | Mean, 68.2 | Up to 25 years | DFS and OS | Nuclear | 76.5 | No |
| Gulubova [20] | 2010 | Bulgary | I-IV | 138 | 1997-2006 | Santa Cruz Biotechnology Inc | 1:50 | Colon/rectum | Median, 65 | Median, 37.6 months | OS | Nuclear | 88.4 | No |
| Li [21] | 2011 | China | I-IV | 147 | 2003-2004 | Zhongshan Biotechnology | 1:150 | Colon | NA | Up to 5 years | DFS and OS | Nuclear | 74.1 | No |
| Baraniskin [22] | 2011 | Germany | IV | 190 | NA | Santa Cruz Biotechnology Inc | 1:100 | Colon/rectum | Mean, 64.4 | NA | OS | Nuclear | 65.8 | Yes |
| Ahn [23] | 2011 | South Korea | I-IV | 429 | 1991-2000 | Santa Cruz Biotechnology Inc | 1:200 | Colon/rectum | Mean, 57 | Median, 56 months | DFS | NA | 47.3 | Yes |
| Isaksson-Mettävainio [24] | 2012 | Sweden | I-IV | 441 | 1995-2003 | Santa Cruz Biotechnology Inc | 1:100 | Colon/rectum | NA | NA | CSS | Nuclear | 80.3 | Yes |
| Lampropoulos [25] | 2012 | Greece | I-IV | 195 | 2005-2006 | Santa Cruz Biotechnology Inc | 1:100 | Colon/rectum | Mean, 68.6 | Median, 56 months | CSS | Both | 61.5 | No |
| Roth [26] | 2012 | Switzerland | II-III | 1381 | NA | Santa Cruz Biotechnology Inc | 0.2 mg/ml | Colon | Median, 60 | Median, 69 months | OS and DFS | NA | 78.8 | Yes |
| Voorneveld [16] | 2013 | Netherlands | I-IV | 209 | 1983-2004 | Santa Cruz Biotechnology Inc | 1:400 | Colon | Mean, 68.9 | Median, 65 months | CSS | Nuclear | 60 | No |